ZYMERGEN INC.

(ZY)
  Report
Delayed Nasdaq  -  05/19 04:00:00 pm EDT
1.320 USD   +3.94%
05/12ZYMERGEN INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/12ZYMERGEN : Q1 Earnings Snapshot
AQ
05/12TRANSCRIPT : Zymergen Inc., Q1 2022 Earnings Call, May 12, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zymergen Announces New Drug Discovery Business Based Around Their Proprietary Synthetic Biology Platform

01/09/2022 | 09:00pm EDT

Zymergen announced a new drug discovery business based around their proprietary synthetic biology platform and what is believed to be the large metagenomics database, combining both size and quality. This new business leverages Zymergen’s differentiated access to natural products as a source of diverse chemical matter and augments Zymergen’s existing advanced materials programs, capitalizing on years of prior research and development in synthetic biology. Zymergen's metagenomics database - which contains a breadth and depth of metagenomic information rivaling all publicly available datasets combined - provides access to a vast reservoir of novel natural products, including molecules from uncultured microbes. With this resource, Zymergen scientists have been able to confirm currently marketed blockbuster drugs and molecules in late clinical development, and discover novel modulators of important oncology targets. By combining next-gen sequencing with proprietary machine learning and informatics, Zymergen’s platform transforms the search for structurally novel bioactive molecules from tedious screening campaigns to a rapid and accurate digital database search for a therapeutic target of interest. Zymergen’s initial drug discovery pipeline is focused on high-value oncology targets where precision medicine and Zymergen’s distinctive, complex molecules are expected to provide competitive and therapeutic advantages.


© S&P Capital IQ 2022
All news about ZYMERGEN INC.
05/12ZYMERGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/12ZYMERGEN : Q1 Earnings Snapshot
AQ
05/12TRANSCRIPT : Zymergen Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12Earnings Flash (ZY) ZYMERGEN Reports Q1 Revenue $4.8M, vs. Street Est of $3.34M
MT
05/12Zymergen Reports Preliminary First Quarter 2022 Financial Results
AQ
05/12Zymergen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10TRANSCRIPT : Zymergen Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-..
CI
04/29Zymergen to Participate in the BofA Securities 2022 Healthcare Conference
AQ
04/13Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022
AQ
04/13Goldman Sachs Adjusts Zymergen's Price Target to $4 from $6, Keeps Neutral Rating
MT
More news
Analyst Recommendations on ZYMERGEN INC.
More recommendations
Financials (USD)
Sales 2022 14,0 M - -
Net income 2022 -294 M - -
Net cash 2022 91,0 M - -
P/E ratio 2022 -0,43x
Yield 2022 -
Capitalization 131 M 131 M -
EV / Sales 2022 2,85x
EV / Sales 2023 4,18x
Nbr of Employees 505
Free-Float 92,5%
Chart ZYMERGEN INC.
Duration : Period :
Zymergen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZYMERGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 1,27 $
Average target price 2,88 $
Spread / Average Target 126%
EPS Revisions
Managers and Directors
Jay T. Flatley Chairman & Chief Executive Officer
Enakshi Singh Chief Financial Officer
Zachariah Serber Director & Chief Science Officer
Rohit Sharma Independent Director
Matthew Ocko Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ZYMERGEN INC.-81.02%131
SHIN-ETSU CHEMICAL CO., LTD-8.23%59 239
BASF SE-19.30%47 269
DUPONT DE NEMOURS, INC.-20.43%32 688
SASOL LIMITED52.25%15 497
FMC CORPORATION8.01%14 948